Previous research has shown that quantitative electroencephalography (qEEG) can monitor treatment of Alzheimer's Disease (AD). This study investigated the ability of a qEEG measure based on EEG variance, combined with a delayed recognition memory task, to measure treatment effects on patients with AD.
Three AD patients with very mild AD (CDR=0.5, FAST stage 3) were monitored with task specific EEG at multiple time points before and after medication treatment. Patients had their EEG recorded while performing a recognition memory task. A measure of (normalized) variance was applied to the EEG data. To the extent possible, the subjects received this treatment monitoring multiple times. These patients were monitored a total of 14 times, which yielded 11 measurements of qEEG change during the course of treatment.
The direction of change in patients' qEEG values agreed with patients' medication treatment on 10 out of 11 occasions, p < 0.006 (binomial test) and was more accurate than monitoring with the relative theta power, p < 0.05. The results of this monitoring also showed that the qEEG measure accurately reflected treatment in a dose dependent manner. These results were independent of the specific medication monitored; Galantamine, Memantine, Nicotine, and Rivastigmine. In conclusion, this qEEG method may be useful for measuring AD treatment responses.
DuffyFHBurchfielJLLombrosoCT. Brain electrical activity mapping (BEAM): a method for extending the clinical utility of EEG and evoked potential data. Ann Neurol1979;5:309–321.
2.
DuffyFH. The BEAM method for neurophysiological diagnosis. Ann N Y Acad Sci1985;457:19–34.
3.
PritchardWSDukeDWCoburnKLEEG-based, neural-net predictive classification of Alzheimer's disease versus control subjects is augmented by non-linear EEG measures. Electroencephalogr Clin Neurophysiol1994;91:118–130.
4.
GibbsFA. Electrical activity of the brain. Ann Rev Physiol1945;7:427–454.
5.
JohnERPrichepLSFridmanJEastonP. Neurometrics: computer-assisted differential diagnosis of brain dysfunctions. Science1988;239:162–169.
6.
BarlowJS. The Electroencephalogram: Its Patterns and Origins. Cambridge, Mass: MIT Press; 1993;13:456.
7.
LüdersHNoachtarS. Atlas and Classification of Electroencephalography. Philadelphia: Saunders; 2000;14:203.
8.
NiedermeyerELopes daSilva FH. Electroencephalography: Basic Principles, Clinical Applications, and Related Fields. 4th ed.Baltimore: Williams & Wilkins; 1999; 1258.
9.
EbersoleJSPedleyTA. Current Practice of Clinical Electroencephalography. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2003;16:973–974.
10.
LeuchterAFReadSLShapiraJStable bimodal response to cholinomimetic drugs in Alzheimer's disease: brain mapping correlates. Neuropsychopharmacology1991;4:165–173.
11.
BalkanSYarasNMihciEEffect of donepezil on EEG spectral analysis in Alzheimer's disease. Acta Neurol Belg2003;103:164–169.
12.
AlmkvistOJelicVAmberlaKResponder characteristics to a single oral dose of Cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord2001;12:22–32.
13.
AlhainenKPartanenJReinikainenKDiscrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease. Neurosci Lett1991;127:113–116.
14.
AlhainenKRiekkinenPJSr.Discrimination of Alzheimer patients responding to Cholinesterase inhibitor therapy. Acta Neurol Scand Suppl1993;149:16–21.
15.
KnottVMohrEMahoneyCIlivitskyV. Quantitative electroencephalography in Alzheimer's disease: comparison with a control group, population norms and mental status. J Psychiatr Neurosci2001;26:106–116.
16.
KnottVMohrEMahoneyCIlivitskyV. Pharmaco-EEG test dose response predicts Cholinesterase inhibitor treatment outcome in Alzheimer's disease. Methods Find Exp Clin Pharmacol2000;22:115–122.
17.
LanctotKLHerrmannNLouM. Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. J Psychiatry Neurosci2003;28:13–26.
18.
KoganEAKorczynADVirchovskyRGEEG changes during long-term treatment with donepezil in Alzheimer's disease patients. J Neural Transm2001;108:1167–1173.
19.
ReevesRRStruveFAPatrickG. The effects of donepezil on quantitative EEG in patients with Alzheimer's disease. Clin Electroencephalogr2002;33:93–96.
20.
PasquierFGrymonprezLLebertFVan der LindenM. Memory impairment differs in frontotemporal dementia and Alzheimer's disease. Neurocase2001;7:161–171.
21.
SouliezLPasquierFLebertFGeneration effect in short-term verbal and visuospatial memory: comparisons between dementia of Alzheimer type and dementia of frontal lobe type. Cortex1996;32:347–356.
22.
KopelmanMD. Non-verbal, short-term forgetting in the alcoholic Korsakoff syndrome and Alzheimer-type dementia. Neuropsychologia1991;29:737–747.
23.
MorrisRGBaddeleyAD. Primary and working memory functioning in Alzheimer-type dementia. J Clin Exp Neuropsychol1988;10:279–296.
24.
TombergCDesmedtJE. Non-averaged human brain potentials in somatic attention: the short-latency cognition-related P40 component. J Physiol1996;496(Pt 2): 559–574.
25.
TombergC. Cognitive N140 electrogenesis and concomitant 40 Hz synchronization in mid-dorsolateral prefrontal cortex (area 46) identified in non-averaged human brain potentials. Neurosci Lett1999;266:141–144.
26.
HalgrenEBaudenaPHeitGSpatio-temporal stages in face and word processing. II. Depth-recorded potentials in the human frontal and Rolandic cortices. J Physiol Paris1994;88:51–80.
27.
WagnerADDesmondJEGloverGHGabrieliJD. Prefrontal cortex and recognition memory: functional-MRI evidence for context-dependent retrieval processes. Brain1998;121(Pt 10): 1985–2002.
28.
RanganathC. The 3-D prefrontal cortex: hemispheric asymmetries in prefrontal activity and their relation to memory retrieval processes. J Cogn Neurosci2004;16:903–907.
29.
RanganathCPallerKA. Frontal brain potentials during recognition are modulated by requirements to retrieve perceptual detail. Neuron1999;22:605–613.
30.
JohnsonJSOlshausenBA. Timecourse of neural signatures of object recognition. J Vis2003;3:499–512.
31.
SneddonRShankleWRHaraJEEG detection of early Alzheimer's disease using psychophysical tasks. Clin EEG Neurosci2005;36:140–150.
32.
TsallisC. Possible generalization of Boltzmann-Gibbs statistics. J Statistic Physics1988;52:479–487.
33.
ShannonCWeaverW. The Mathematical Theory of Communication. Urbana: Univeristy of Illinois Press; 1963.
34.
JohannsenP. Long-term Cholinesterase inhibitor treatment of Alzheimer's disease. CNS Drugs2004;18:757–768.
35.
WilliamsBRNazariansAGillMA. A review of rivastigmine: a reversible Cholinesterase inhibitor. Clin Ther2003;25:1634–1653.
36.
SternEABacskaiBJHickeyGACortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci2004;24:4535–4540.
37.
HarrisKDCsicsvariJHiraseHOrganization of cell assemblies in the hippocampus. Nature2003;424:552–556.
38.
JohnER. The neurophysics of consciousness. Brain Res Brain Res Rev2002;39:1–28.
39.
TsallisTC. Possible generalization of Boltzmann-Gibbs statistics. J Statistic Physics1988;52:479–487.
